Author Archives: Gastroenterology Journal
MELD 3.0: The Model for End-stage Liver Disease Updated for the Modern Era
The model for end-stage liver disease (MELD) has been established as a reliable indicator of short-term survival in patients with end-stage liver disease. The current version (MELDNa), consisting of INR and serum bilirubin, creatinine, and sodium, has … Continue reading
Posted in News
Comments Off on MELD 3.0: The Model for End-stage Liver Disease Updated for the Modern Era
Molecular characterization of limited ulcerative colitis reveals novel biology and predictors of disease extension
Disease extent varies in ulcerative colitis (UC) from proctitis to left-sided colitis to pancolitis and is a major prognostic factor. When the extent of UC is limited there is often a sharp demarcation between macroscopically involved and uninvolved ar… Continue reading
Posted in News
Comments Off on Molecular characterization of limited ulcerative colitis reveals novel biology and predictors of disease extension
Single cell DNA sequencing reveals punctuated and gradual clonal evolution in hepatocellular carcinoma
Copy number alterations (CNAs), elicited by genome instability, is a major source of intratumor heterogeneity. How CNAs evolve in hepatocellular carcinoma (HCC) remains unknown. Continue reading
Posted in News
Comments Off on Single cell DNA sequencing reveals punctuated and gradual clonal evolution in hepatocellular carcinoma
LTE Reply to 21-00786 and 21-01414
Posted in News
Comments Off on LTE Reply to 21-00786 and 21-01414
The tight junction protein ZO-1 is dispensable for barrier function but critical for effective mucosal repair
S AND AIMS: Increased permeability is implicated in the pathogenesis of intestinal disease. In vitro and in vivo studies have linked downregulation of the scaffolding protein ZO-1, encoded by the TJP1 gene, to increased tight junction permeability. Thi… Continue reading
Posted in News
Comments Off on The tight junction protein ZO-1 is dispensable for barrier function but critical for effective mucosal repair
775a Risankizumab Induction Therapy in Patients With Moderate-to-Severe Crohn’s Disease with Intolerance or Inadequate Response to Conventional and/or Biologic Therapy: Results from the Phase 3 ADVANCE Study
Risankizumab (RZB) is a monoclonal antibody against interleukin-23, a key cytokine in the pathogenesis of inflammatory bowel disease. Phase 2 studies have shown efficacy and safety of RZB in patients with Crohn’s disease (CD). Here we report results of… Continue reading
Posted in News
Comments Off on 775a Risankizumab Induction Therapy in Patients With Moderate-to-Severe Crohn’s Disease with Intolerance or Inadequate Response to Conventional and/or Biologic Therapy: Results from the Phase 3 ADVANCE Study
713b A Multi-Systems Approach with Big Data from Adverse Event Reporting and Health Records, Clinical Biospecimens, and Experimental Animal Data Reveal That Retinoids Impact Asparaginase-Associated Pancreatitis Outcomes in Leukemic Patients
Asparaginase is a crucial cornerstone chemotherapy for the most common cancer in children, acute lymphoblastic leukemia (ALL). However, a major concern is that 5-10% of all asparaginase users develop the painful, life-threatening complication of pancre… Continue reading
Posted in News
Comments Off on 713b A Multi-Systems Approach with Big Data from Adverse Event Reporting and Health Records, Clinical Biospecimens, and Experimental Animal Data Reveal That Retinoids Impact Asparaginase-Associated Pancreatitis Outcomes in Leukemic Patients
775b Olamkicept, an IL-6 Trans-Signaling Inhibitor, is Effective for Induction of Response and Remission in A Randomized, Placebo-Controlled Trial in Moderate to Severe Ulcerative Colitis
IL-6 trans-signaling blockade inhibits chronic inflammation in human lamina propria1. Trans-signaling inhibition may have safety advantages over pan-IL-6 inhibitors (i.e. IL-6 or IL-6R antibodies) by preserving membrane IL-6R signaling. We evaluated th… Continue reading
Posted in News
Comments Off on 775b Olamkicept, an IL-6 Trans-Signaling Inhibitor, is Effective for Induction of Response and Remission in A Randomized, Placebo-Controlled Trial in Moderate to Severe Ulcerative Colitis
713c Dietary Fat Increases Intestinal Fructose Conversion to Glycerate that Accumlates in Circulation, Driving Glucose Intolerance
The development of type II diabetes mellitus (T2DM) is strongly associated with consuming a western diet, high in sugars and fats. Metabolites from both dietary fats and carbohydrates can regulate each other through transcriptional regulators like carb… Continue reading
Posted in News
Comments Off on 713c Dietary Fat Increases Intestinal Fructose Conversion to Glycerate that Accumlates in Circulation, Driving Glucose Intolerance
775d Ustekinumab Versus Adalimumab for Induction and Maintenance Therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE Study
Head-to-head trials are important to inform patient (pt) and physician choice. We studied the efficacy and safety of ustekinumab (UST) vs adalimumab (ADA) through 1 year in biologic-naïve pts with moderate-to-severe Crohn’s disease (CD). Continue reading
Posted in News
Comments Off on 775d Ustekinumab Versus Adalimumab for Induction and Maintenance Therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE Study